The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: A meta-analysis of the literatures

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Yu, Ting ^a   Zhang, Qiongwen ^a   Zheng, Tianying ^a   Shi, Huashan ^a   Liu, Yang ^a   Feng, Shijian ^a   Hao, Meiqin ^a   Ye, Lei ^a   Wu, Xueqian ^a   Yang, Cheng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOCHEMICAL RECURRENCE; CONFORMAL RADIOTHERAPY; DISEASE SEVERITY; GASTROINTESTINAL TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; META ANALYSIS; OVERALL SURVIVAL; PROSTATE CANCER; RECTUM HEMORRHAGE; UROGENITAL TRACT DISEASE; ACUTE DISEASE; ADVERSE EFFECTS; COMPARATIVE STUDY; GASTROINTESTINAL DISEASES; HEMORRHAGE; MALE; ODDS RATIO; PATHOLOGY; PROSTATIC NEOPLASMS; PUBLISHING; RECTUM; RISK FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ACUTE DISEASE; GASTROINTESTINAL DISEASES; HEMORRHAGE; HUMANS; MALE; ODDS RATIO; PROSTATIC NEOPLASMS; PUBLICATION BIAS; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84971324178     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0154499     Document Type: Article

References (76)

1. Siegel RL, Miller KD, Jemal A (2015) Cancer Statistics, 2015. Ca-a Cancer Journal for Clinicians 65: 5-29. doi: 10.3322/caac.21254 PMID: 25559415
2. Hanks GE (2000) Conformal radiotherapy for prostate cancer. Annals of Medicine 32: 57-63. PMID: 10711579
3. Jani AB, Hellman S (2003) Early prostate cancer: clinical decision-making. Lancet 361: 1045-1053. PMID: 12660074
4. Crook J, Ots AF (2013) Prognostic Factors for Newly Diagnosed Prostate Cancer and Their Role in Treatment Selection. Seminars in Radiation Oncology 23: 165-172. doi: 10.1016/j.semradonc.2013.01.002 PMID: 23763882
5. Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28: 1117-1123. doi: 10.1200/JCO.2009.26.0133 PMID: 20124165
6. Kramer KM, Bennett CL, Pickard AS, Lyons EA, Wolf MS, et al. (2005) Patient preferences in prostate cancer: a clinician's guide to understanding health utilities. Clin Prostate Cancer 4: 15-23. PMID: 15992457
7. Beckendorf V, Guerif S, Le Prise E, Cosset JM, Bougnoux A, et al. (2011) 70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of Getug 06 Randomized Trial. International Journal of Radiation Oncology Biology Physics 80: 1056-1063.
8. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, et al. (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncology 8: 475-487. PMID: 17482880
9. Ohri N, Dicker AP, Showalter TN (2012) Late toxicity rates following definitive radiotherapy for prostate cancer. Canadian Journal of Urology 19: 6373-6380. PMID: 22892261
10. Peeters STH, Heemsbergen WD, Koper PCM, van Putten WLJ, Slot A, et al. (2006) Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology 24: 1990-1996. PMID: 16648499
11. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, et al. (2002) Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics 53: 1097-1105.
12. Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, et al. (2008) Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 71: 330-337. doi: 10.1016/j.ijrobp.2007.10.004 PMID: 18164858
13. Viani GA, Stefano EJ, Afonso SL (2009) Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 74: 1405-1418. doi: 10.1016/j.ijrobp.2008.10.091 PMID: 19616743
14. Dearnaley DP, Sydes MR, Langley RE, Graham JD, Huddart RA, et al. (2007) The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiother Oncol 83: 31-41. PMID: 17391791
15. Ohri N, Dicker AP, Showalter TN (2012) Late toxicity rates following definitive radiotherapy for prostate cancer. Can J Urol 19: 6373-6380. PMID: 22892261
16. Haas GP, Delongchamps NB, Jones RF, Chandan V, Serio AM, et al. (2007) Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst 99: 1484-1489. PMID: 17895474
17. Merglen A, Schmidlin F, Fioretta G, Verkooijen HM, Rapiti E, et al. (2007) Short- and long-term mortality with localized prostate cancer. Arch Intern Med 167: 1944-1950. PMID: 17923593
18. Penson DF, Litwin MS (2003) Quality of life after treatment for prostate cancer. Curr Urol Rep 4: 185-195. PMID: 12756081
19. Daskivich TJ, Chamie K, Kwan L, Labo J, Palvolgyi R, et al. (2011) Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer 117: 2058-2066. doi: 10.1002/cncr.25751 PMID: 21523717
20. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, et al. (2008) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial (vol 294, pg 1233, 2005). Jama-Journal of the American Medical Association 299: 899-900.
21. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, et al. (1998) Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41: 491-500. PMID: 9635694
22. Fiveash JB, Hanks G, Roach M, Wang S, Vigneault E, et al. (2000) 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review. Int J Radiat Oncol Biol Phys 47: 335-342. PMID: 10802357
23. Marta GN, Silva V, Carvalho HD, de Arruda FF, Hanna SA, et al. (2014) Intensity-modulated radiation therapy for head and neck cancer: Systematic review and meta-analysis. Radiotherapy and Oncology 110: 9-15. doi: 10.1016/j.radonc.2013.11.010 PMID: 24332675
24. Zelefsky MJ, Yamada Y, Kollmeier MA, Shippy AM, Nedelka MA (2008) Long-Term Outcome Following Three-Dimensional Conformal/Intensity-Modulated External-Beam Radiotherapy for Clinical Stage T3 Prostate Cancer. European Urology 53: 1172-1179. doi: 10.1016/j.eururo.2007.12.030 PMID: 18222596
25. Damast S, Wolden S, Lee N (2012) Marginal recurrences after selective targeting with intensity-modulated radiotherapy for oral tongue cancer. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 34: 900-906.
26. Lee N, Puri DR, Blanco AI, Chao KSC (2007) Intensity-modulated radiation therapy in head and neck cancers: An update. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 29: 387-400.
27. Ruben JD, Davis S, Evans C, Jones P, Gagliardi F, et al. (2008) The effect of intensity-modulated radiotherapy on radiation-induced second malignancies. Int J Radiat Oncol Biol Phys 70: 1530-1536. doi: 10.1016/j.ijrobp.2007.08.046 PMID: 18207670
28. Schneider U, Lomax A, Pemler P, Besserer J, Ross D, et al. (2006) The impact of IMRT and proton radiotherapy on secondary cancer incidence. Strahlentherapie und Onkologie 182: 647-652. PMID: 17072522
29. Bednarz B, Athar B, Xu XG (2010) A comparative study on the risk of second primary cancers in out-of-field organs associated with radiotherapy of localized prostate carcinoma using Monte Carlo-based accelerator and patient models. Medical Physics 37: 1987-1994. PMID: 20527532
30. Murray L, Henry A, Hoskin P, Siebert FA, Venselaar J (2014) Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique. Radiother Oncol 110: 213-228. doi: 10.1016/j.radonc.2013.12.012 PMID: 24485765
31. Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, et al. (1991) Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 21: 935-939. PMID: 1917622
32. (1995) Late effects consensus conference: RTOG/EORTC. Radiother Oncol 35: 5-7. PMID: 7569013
33. Wong WW, Vora SA, Schild SE, Ezzell GA, Andrews PE, et al. (2009) Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy. Cancer 115: 5596-5606. doi: 10.1002/cncr.24558 PMID: 19670452
34. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834. PMID: 9921604
35. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. PMID: 9310563
36. Alongi F, Fiorino C, Cozzarini C, Broggi S, Perna L, et al. (2009) IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol 93: 207-212. doi: 10.1016/j.radonc.2009.08.042 PMID: 19766338
37. Goenka A, Magsanoc JM, Pei X, Schechter M, Kollmeier M, et al. (2011) Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy. Eur Urol 60: 1142-1148. doi: 10.1016/j.eururo.2011.08.006 PMID: 21855208
38. Ashman JB, Zelefsky MJ, Hunt MS, Leibel SA, Fuks Z (2005) Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 63: 765-771. PMID: 15913914
39. Cho JH, Lee CG, Kang DR, Kim J, Lee S, et al. (2009) Positional reproducibility and effects of a rectal balloon in prostate cancer radiotherapy. J Korean Med Sci 24: 894-903. doi: 10.3346/jkms.2009.24.5.894 PMID: 19794990
40. Dolezel M, Odrazka K, Vaculikova M, Vanasek J, Sefrova J, et al. (2010) Direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy. Strahlentherapie und Onkologie 186: 197-202. doi: 10.1007/s00066-010-2065-x PMID: 20354663
41. Dolezel M, Odrazka K, Zouhar M, Vaculikova M, Sefrova J, et al. (2015) Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer. Strahlenther Onkol 191: 338-346. doi: 10.1007/s00066-014-0806-y PMID: 25589224
42. Forsythe K, Blacksburg S, Stone N, Stock RG (2012) Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 83: 630-635. doi: 10.1016/j.ijrobp.2011.06.2013 PMID: 22099032
43. Jani AB, Gratzle J, Correa D (2007) Influence of intensity-modulated radiotherapy on acute genitourinary and gastrointestinal toxicity in the treatment of localized prostate cancer. Technol Cancer Res Treat 6: 11-15. PMID: 17241095
44. Kim H, Kim JW, Hong SJ, Rha KH, Lee CG, et al. (2014) Treatment outcome of localized prostate cancer by 70 Gy hypofractionated intensity-modulated radiotherapy with a customized rectal balloon. Radiat Oncol J 32: 187-197. doi: 10.3857/roj.2014.32.3.187 PMID: 25324991
45. Kupelian PA, Reddy CA, Carlson TP, Altsman KA, Willoughby TR (2002) Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys 53: 904-912. PMID: 12095556
46. Odrazka K, Dolezel M, Vanasek J, Vaculikova M, Zouhar M, et al. (2010) Late toxicity after conformal and intensity-modulated radiation therapy for prostate cancer: impact of previous surgery for benign prostatic hyperplasia. Int J Urol 17: 784-790. doi: 10.1111/j.1442-2042.2010.02592.x PMID: 20604816
47. Ratnayake G, Martin J, Plank A, Wong W (2014) Incremental changes verses a technological quantum leap: the additional value of intensity-modulated radiotherapy beyond image-guided radiotherapy for prostate irradiation. J Med Imaging Radiat Oncol 58: 503-510. PMID: 25243269
48. Sharma NK, Li T, Chen DY, Pollack A, Horwitz EM, et al. (2007) Intensity Modulated Radiation Therapy Reduces Gastrointestinal Toxicity in Patients Treated with Androgen Deprivation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 69: S10. PMID: 20664712
49. Someya M, Hori M, Tateoka K, Nakata K, Takagi M, et al. (2015) Results and DVH analysis of late rectal bleeding in patients treated with 3D-CRT or IMRT for localized prostate cancer. J Radiat Res 56: 122-127. doi: 10.1093/jrr/rru080 PMID: 25212601
50. Sveistrup J, af Rosenschold PM, Deasy JO, Oh JH, Pommer T, et al. (2014) Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiat Oncol 9: 44. doi: 10.1186/1748-717X-9-44 PMID: 24495815
51. Troeller A, Yan D, Marina O, Schulze D, Alber M, et al. (2015) Comparison and limitations of DVH-based NTCP models derived from 3D-CRT and IMRT data for prediction of gastrointestinal toxicities in prostate cancer patients by using propensity score matched pair analysis. Int J Radiat Oncol Biol Phys 91: 435-443. doi: 10.1016/j.ijrobp.2014.09.046 PMID: 25636766
52. Vora SA, Wong WW, Schild SE, Ezzell GA, Halyard MY (2007) Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 68: 1053-1058. PMID: 17398023
53. Zelefsky MJ, Fuks Z, Happersett L, Lee HJ, Ling CC, et al. (2000) Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 55: 241-249. PMID: 10869739
54. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, et al. (2008) Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70: 1124-1129. doi: 10.1016/j.ijrobp.2007.11.044 PMID: 18313526
55. Shu HKG, Lee TT, Vigneault E, Xia P, Pickett B, et al. (2001) Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer. Urology 57: 102-107.
56. Wortel RC, Incrocci L, Pos FJ, Lebesque JV, Witte MG, et al. (2015) Acute Toxicity After Image-Guided Intensity Modulated Radiation Therapy Compared to 3D Conformal Radiation Therapy in Prostate Cancer Patients. Int J Radiat Oncol Biol Phys 91: 737-744. doi: 10.1016/j.ijrobp.2014.12.017 PMID: 25752386
57. Matzinger O, Duclos F, Van Den Bergh A, Carrie C, Kitsios P, et al. (2009) Acute toxicity of curative radiotherapy for intermediate risk localized prostate cancer in the EORTC trial 22991. European Journal of Cancer, Supplement 7: 151-152.
58. Shu HK, Lee TT, Vigneauly E, Xia P, Pickett B, et al. (2001) Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer. Urology 57: 102-107.
59. Staffurth J, Radiotherapy Development B (2010) A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol) 22: 643-657.
60. Roach M 3rd (2004) Reducing the toxicity associated with the use of radiotherapy in men with localized prostate cancer. Urol Clin North Am 31: 353-366. PMID: 15123413
61. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, et al. (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70: 67-74. PMID: 17765406
62. Hall EJ, Wuu CS (2003) Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 56: 83-88. PMID: 12694826
63. Van de Werf E, Lievens Y, Verstraete J, Pauwels K, Van den Bogaert W (2009) Time and motion study of radiotherapy delivery: Economic burden of increased quality assurance and IMRT. Radiother Oncol 93: 137-140. doi: 10.1016/j.radonc.2009.07.007 PMID: 19732984
64. Hummel S, Simpson EL, Hemingway P, Stevenson MD, Rees A (2010) Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technol Assess 14: 1-, iii-iv.
65. Bauman G, Rumble RB, Chen J, Loblaw A, Warde P (2012) Intensity-modulated Radiotherapy in the Treatment of Prostate Cancer. Clinical Oncology 24: 461-473. doi: 10.1016/j.clon.2012.05.002 PMID: 22673744
66. Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, et al. (1999) Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 353: 267-272. PMID: 9929018
67. Michalski JM, Winter K, Purdy JA, Parliament M, Wong H, et al. (2005) Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys 62: 706-713. PMID: 15936549
68. Michalski JM, Winter K, Purdy JA, Wilder RB, Perez CA, et al. (2003) Preliminary evaluation of lowgrade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys 56: 192-198. PMID: 12694838
69. Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, et al. (2005) Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61: 1019-1034. PMID: 15752881
70. Budaus L, Bolla M, Bossi A, Cozzarini C, Crook J, et al. (2012) Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol 61: 112-127. doi: 10.1016/j.eururo.2011.09.027 PMID: 22001105
71. Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO (2010) Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 76: S123-129. doi: 10.1016/j.ijrobp.2009.03.078 PMID: 20171506
72. Phan J, Swanson DA, Levy LB, Kudchadker RJ, Bruno TL, et al. (2009) Late rectal complications after prostate brachytherapy for localized prostate cancer: incidence and management. Cancer 115: 1827-1839. doi: 10.1002/cncr.24223 PMID: 19248043
73. Jackson A, Skwarchuk MW, Zelefsky MJ, Cowen DM, Venkatraman ES, et al. (2001) Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys 49: 685-698. PMID: 11172950
74. Ailleres N, Azria D, Thezenas S, Barbier N, Fenoglietto P, et al. (2004) [Pilot study of conformal intensity modulated radiation therapy for localized prostate cancer]. Cancer Radiother 8: 59-69. PMID: 15063872
75. Livi L, Detti B, Meattini M, Sanchez LJ, Biti GP (2007) [Organ-confined prostate cancer: treatment with high doses of radioterapy (intensity modulated radiotherapy)]. Actas Urol Esp 31: 611-616. PMID: 17896557
76. Treutwein M, Hipp M, Bogner L (2008) Direct step & shoot: New module for prostate cancer intensity-modulated radiotherapy. Nowotwory 58: 154-156.